La Jolla Pharmaceutical Company (LJPC)

$ 4.7
+0.04 (+0.86%)
Symbol LJPC
Price $ 4.7
Beta 2.260
Volume Avg. 0.10M
Market Cap 0.129B
Shares () -
52 Week Range 3.35-7.85
1y Target Est -
DCF Unlevered LJPC DCF ->
DCF Levered LJPC LDCF ->
ROE -16.76% Sell
ROA 12.38% Buy
Operating Margin -
Debt / Equity -246.61% Sell
P/E 12.37 Strong Buy
P/B -1.89 Sell


Consensus EPS

Upgrades & Downgrades

Latest LJPC news

Dr. George Tidmarsh
Nasdaq Capital Market

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), an investigational product to treat conditions characterized by iron overload. The company was founded in 1989 and is headquartered in San Diego, California.